Get the Stockscreener App
2.34
2.09%
-0.05
After Hours:
2.36
0.02
+0.85%
Protalix BioTherapeutics Inc. stock is traded at $2.34, with a volume of 411.95K.
It is down -2.09% in the last 24 hours and down -3.70% over the past month.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
See More
Previous Close:
$2.39
Open:
$2.31
24h Volume:
411.95K
Relative Volume:
0.51
Market Cap:
$186.57M
Revenue:
$63.63M
Net Income/Loss:
$10.62M
P/E Ratio:
46.80
EPS:
0.05
Net Cash Flow:
$-8.64M
1W Performance:
+1.74%
1M Performance:
-3.70%
6M Performance:
-22.00%
1Y Performance:
+82.81%
1-Day Range:
$2.2501
$2.38
1-Week Range:
$2.22
$2.42
52-Week Range:
$1.16
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Name
Protalix BioTherapeutics Inc.
Sector
Industry
Phone
972 4 988 9488
Address
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.34 | 190.56M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-17-17 | Reiterated | Rodman & Renshaw | Buy |
| Apr-04-16 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-15 | Upgrade | Jefferies | Hold → Buy |
| Nov-12-14 | Reiterated | R. F. Lafferty | Buy |
| Jan-24-14 | Initiated | R. F. Lafferty | Buy |
| May-02-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-02-12 | Reiterated | Oppenheimer | Outperform |
| Apr-30-12 | Downgrade | Auriga | Buy → Hold |
| Oct-13-11 | Initiated | Morgan Joseph | Hold |
| Mar-17-11 | Downgrade | WBB Securities | Strong Buy → Buy |
| Nov-09-10 | Reiterated | Oppenheimer | Outperform |
| Oct-14-10 | Reiterated | UBS | Buy |
| Dec-02-09 | Reiterated | Hapoalim | Outperform |
| Sep-22-09 | Initiated | Canaccord Adams | Buy |
| Sep-02-09 | Initiated | Hapoalim | Outperform |
| Dec-01-08 | Reiterated | Oppenheimer | Outperform |
| Mar-11-08 | Initiated | UBS | Buy |
| Nov-20-07 | Initiated | CIBC Wrld Mkts | Sector Outperform |
View All
Protalix BioTherapeutics Inc. Stock (PLX) Latest News
How Protalix BioTherapeutics Inc. (DE) stock performs in volatility spikesJuly 2025 Review & Daily Technical Forecast Reports - newser.com
Protalix and Chiesi seek EMA re-examination of Elfabrio dosing opinion - Proactive financial news
Chiesi and Protalix seek review of EMA’s negative opinion on Elfabrio - Investing.com Australia
Real time scanner hits for Protalix BioTherapeutics Inc. explainedMarket Risk Report & Community Trade Idea Sharing Platform - newser.com
How to integrate Protalix BioTherapeutics Inc. into portfolio analysis toolsEarnings Recap Report & Weekly Top Gainers Alerts - newser.com
Relative strength of Protalix BioTherapeutics Inc. in sector analysisPortfolio Update Summary & Daily Stock Momentum Reports - newser.com
What makes Protalix BioTherapeutics Inc. stock attractive to growth fundsJuly 2025 Short Interest & Fast Entry and Exit Trade Plans - newser.com
Is Protalix BioTherapeutics Inc. (PBDA) stock a contrarian opportunityJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
Analyzing recovery setups for Protalix BioTherapeutics Inc. investorsCPI Data & Expert Approved Momentum Ideas - newser.com
Custom strategy builders for tracking Protalix BioTherapeutics Inc.July 2025 Gainers & Low Drawdown Momentum Trade Ideas - newser.com
How Protalix BioTherapeutics Inc. stock reacts to job market dataCPI Data & Fast Gaining Stock Strategy Reports - newser.com
Is Protalix BioTherapeutics Inc. still worth holding after the dipMarket Movement Recap & Stepwise Trade Signal Implementation - newser.com
How Protalix BioTherapeutics Inc. (PBDA) stock behaves under inflation pressureStock Surge & Real-Time Market Sentiment Alerts - newser.com
Is Protalix BioTherapeutics Inc. stock attractive for passive investors2025 Market Overview & Trade Opportunity Analysis - newser.com
What Wall Street predicts for Protalix BioTherapeutics Inc. stock priceTrade Signal Summary & High Win Rate Trade Tips - newser.com
Chiesi and Protalix seek review of EMA’s negative opinion on Elfabrio By Investing.com - Investing.com South Africa
Protalix Seeks EMA Re-examination for Elfabrio Dosing - TipRanks
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU - The Manila Times
Chiesi Global Rare Diseases and Protalix BioTherapeutics - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Protalix BioTherapeutics, Inc. (PLX) And Encourages Shareholders to Reach Out - ACCESS Newswire
Why Protalix BioTherapeutics Inc. (DE) stock attracts wealthy investorsBuy Signal & Fast Gain Swing Alerts - newser.com
Is Protalix BioTherapeutics Inc. stock positioned for long term growth2025 Market Sentiment & Free Safe Capital Growth Stock Tips - newser.com
Can Protalix BioTherapeutics Inc. stock deliver consistent earnings growth - newser.com
News impact scoring models applied to Protalix BioTherapeutics Inc.July 2025 Snapshot & Fast Moving Stock Watchlists - newser.com
How Protalix BioTherapeutics Inc. (PBDA) stock trades in high volatilityWeekly Trade Review & Free High Accuracy Swing Entry Alerts - newser.com
Automated trading signals detected on Protalix BioTherapeutics Inc.Weekly Investment Summary & Real-Time Market Sentiment Reports - newser.com
Will Protalix BioTherapeutics Inc. stock benefit from AI adoption2025 Dividend Review & Entry Point Confirmation Signals - newser.com
How Protalix BioTherapeutics Inc. stock performs in weak economyEntry Point & High Accuracy Trade Signal Alerts - newser.com
Will breakout in Protalix BioTherapeutics Inc. lead to full recovery2025 Trade Ideas & AI Powered Market Entry Strategies - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Protalix BioTherapeutics, Inc. (PLX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Will Protalix BioTherapeutics Inc. stock benefit from automation2025 Performance Recap & Step-by-Step Swing Trade Plans - newser.com
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm - The AI Journal
Protalix BioTherapeutics, Inc. (PLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Protalix BioTherapeutics Inc. Stock (PLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):